GlassScriptPhysician profile
Lacia Chapman
NPI 1750482733
$3,934.59
in general payments reported to CMS, 2019-2025
30 companies · $1,003 in 2025
The $1,003 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $84.87 · 2023: $1,182 · 2024: $1,665 · 2025: $1,003.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,850.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,849.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $805.98 | 2022-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $411.73 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $364.97 | 2023-2025 | Vraylar, Qulipta |
| Pfizer INC. | $300.78 | 2023-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $277.00 | 2023-2025 | Caplyta |
| Astrazeneca Pharmaceuticals LP | $225.56 | 2023-2025 | Farxiga, Breztri, Airsupra |
| Antares Pharma, INC. | $183.32 | 2024-2025 | Xyosted, Tlando |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $178.29 | 2023-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $161.91 | 2023-2025 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $155.20 | 2022-2025 | |
| Otsuka America Pharmaceutical, INC. | $130.14 | 2022-2024 | Rexulti |
| Sanofi-Aventis U.S. LLC | $79.83 | 2024-2025 | |
| Amgen INC. | $70.62 | 2022-2025 | Otezla, Repatha, Otezla |
| Glaxosmithkline, LLC. | $70.56 | 2023-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Exact Sciences Corporation | $53.95 | 2024-2025 | Cologuard Collection Kit |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.26 | 2024-2025 | Jardiance, Synjardy |
| Merck Sharp & Dohme LLC | $46.44 | 2023 | |
| Corcept Therapeutics | $45.68 | 2025 | Korlym |
| Lundbeck LLC | $39.48 | 2023-2025 | Vyepti |
| Ardelyx, INC. | $38.85 | 2024-2025 | Ibsrela |
| Janssen Pharmaceuticals, INC | $35.96 | 2024-2025 | Spravato |
| Idorsia Pharmaceuticals US INC | $31.17 | 2023 | Quviviq |
| Kowa Pharmaceuticals America, INC. | $30.63 | 2023 | Livalo, Seglentis |
| Teva Pharmaceuticals USA, INC. | $28.63 | 2025 | Austedo Xr |
| Abbott Laboratories | $27.43 | 2024 | Proclaim |
| Inspire Medical Systems, INC. | $24.75 | 2025 | Inspire |
| Halozyme INC | $19.91 | 2023 | |
| Intra-Sana Laboratories | $17.96 | 2023 | Glycate, Reltone 200 Mg, Reltone 400 Mg |
| Axsome Therapeutics, INC. | $15.15 | 2023 | Auvelity |
| Boston Scientific Corporation | $13.45 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lacia Chapman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.